A systematic review of hypermethylation of p16 gene in esophageal cancer

Cancer Biomarkers

Volumn 13, Issue 4, 2013, Pages 215-226

  Xu, Ruobing ^a   Wang, Fengliang ^b   Wu, Liang ^a   Wang, Jianming ^a   Lu, Cheng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

esophageal neoplasms; Genes; meta analysis; methylation; p16

Indexed keywords

PROTEIN P16;

BLOOD SAMPLING; CANCER GRADING; CANCER PROGNOSIS; CANCER TISSUE; DNA METHYLATION; EMBASE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; HISTOPATHOLOGY; HUMAN; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN METHYLATION; REVIEW; SAMPLE SIZE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION;

ESOPHAGEAL NEOPLASMS; GENES; META-ANALYSIS; METHYLATION; P16;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PUBLICATION BIAS;

EID: 84888618133     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130355     Document Type: Review

References (69)

1. Jemal, A., et al., Global cancer statistics. CA Cancer J Clin, 2011. 61(2): p. 69-90.
2. Edwards, B.K., et al., Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst, 2005. 97(19): p. 1407-27.
3. Chung, C.S., et al., Secondary prevention of esophageal squamous cell carcinoma in areas where smoking, alcohol, and betel quid chewing are prevalent. J Formos Med Assoc, 2010. 109(6): p. 408-21.
4. Wang, J.M., et al., Longitudinal trends of stomach cancer and esophageal cancer in Yangzhong County: a high-incidence rural area of China. Eur J Gastroenterol Hepatol, 2005. 17(12): p. 1339-44.
5. Adams, L., et al., Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev Res (Phila), 2008. 1(5): p. 357-61.
6. De Mattos-Arruda, L., D. Olmos, and J. Tabernero, Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol, 2011. 7(12): p. 1385-97.
7. Zhang, X.M. and M.Z. Guo, The value of epigenetic markers in esophageal cancer. Front Med China, 2010. 4(4): p. 378-84.
8. Momparler, R.L. and V. Bovenzi, DNA methylation and cancer. J Cell Physiol, 2000. 183(2): p. 145-54.
9. Sato, F. and S.J. Meltzer, CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer, 2006. 106(3): p. 483-93.
10. Esteller, M., Epigenetics in cancer. N Engl J Med, 2008. 358(11): p. 1148-59.
11. Kulis, M. and M. Esteller, DNA methylation and cancer. Adv Genet, 2010. 70: p. 27-56.
12. Chin, L., J. Pomerantz, and R.A. DePinho, The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci, 1998. 23(8): p. 291-6.
13. Roth, M.J., et al., p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep, 2006. 15(6): p. 1591-7.
14. Nie, Y., et al., Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis, 2002. 23(10): p. 1713-20.
15. Liberati, A., et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 2009. 6(7): p. e1000100.
16. Higgins, J.P., et al., Measuring inconsistency in metaanalyses. BMJ, 2003. 327(7414): p. 557-60.
17. Bax, L., et al., More than numbers: the power of graphs in meta-analysis. Am J Epidemiol, 2009. 169(2): p. 249-55.
18. Begg, C.B. and J.A. Berlin, Publication bias and dissemination of clinical research. J Natl Cancer Inst, 1989. 81(2): p. 107-15.
19. Fujiwara, S., et al., Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas. Dis Esophagus, 2008. 21(2): p. 125-31.
20. Wang, C., W. Mao, and Z. Ling, [Correlation of multiple methylated tumor suppressor genes in esophageal squamous cell carcinoma]. Journal of Chinese Oncology, 2011. 17(9): p. 673-677.
21. Li, L., et al., DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol, 2012. 22(5): p. 384-94.
22. Baba, Y., M. Watanabe, and H. Baba, A review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today, 2013.
23. Egger, G., et al., Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004. 429(6990): p. 457-63.
24. Das, P.M. and R. Singal, DNA methylation and cancer. J Clin Oncol, 2004. 22(22): p. 4632-42.
25. Powell, E.L., et al., Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol, 2005. 29(11): p. 1497-504.
26. Simao Tde, A., et al., Lower expression of p14ARF and p16INK4a correlates with higher DNMT3B expression in human oesophageal squamous cell carcinomas. Hum Exp Toxicol, 2006. 25(9): p. 515-22.
27. Wang, J., et al., Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 2008. 17(1): p. 118-25.
28. Ishii, T., et al., Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut, 2007. 56(1): p. 13-9.
29. Salam, I., et al., Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir valley: A high-risk area. Mol Cell Biochem, 2009. 332(1-2): p. 51-8.
30. Zhai, R., et al., Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia, 2012. 14(1): p. 29-33.
31. Tsang, J.C. and Y.M. Lo, Circulating nucleic acids in plasma/serum. Pathology, 2007. 39(2): p. 197-207.
32. Marsit, C. and B. Christensen, Blood-derived DNA methylation markers of cancer risk. Adv Exp Med Biol, 2013. 754: p. 233-52.
33. Wu, T., et al., Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: A metaanalysis. Br J Cancer, 2011. 105(1): p. 65-73.
34. Heyn, H. and M. Esteller, DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet, 2012. 13(10): p. 679-92.
35. McDevitt, M.A., Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin Oncol, 2012. 39(1): p. 109-22.
36. Maesawa, C., et al., Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res, 1996. 56(17): p. 3875-8.
37. Wong, D.J., et al., p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res, 1997. 57(13): p. 2619-22.
38. Roncalli, M., et al., Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab Invest, 1998. 78(9): p. 1049-57.
39. Xing, E.P., et al., Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res, 1999. 5(10): p. 2704-13.
40. Xing, E.P., et al., Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis, 1999. 20(1): p. 77-84.
41. Eads, C.A., et al., Fields of aberrant CpG island hypermethylation in Barretts esophagus and associated adenocarcinoma. Cancer Res, 2000. 60(18): p. 5021-6.
42. Kempster, S., et al.,Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. Cancer Lett, 2000. 150(1): p. 57-62.
43. Hibi, K., et al., Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res, 2001. 7(10): p. 3135-8.
44. Bian, Y.S., et al., p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barretts esophagus. Gastroenterology, 2002. 122(4): p. 1113-21.
45. Smeds, J., et al., Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. Carcinogenesis, 2002. 23(4): p. 645-55.
46. Zhang, F., et al., [Methylation and expression of the p16 gene in esophageal squamouscell carcinoma]. Chinese Journal of Clinical and Experimental Patholog, 2002. 18(6): p. 605-607.
47. Sarbia, M., et al., Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer, 2004. 111(2): p. 224-8.
48. Vieth, M., et al., INK4a-ARF alterations in Barretts epithelium, intraepithelial neoplasia and Barretts adenocarcinoma. Virchows Arch, 2004. 445(2): p. 135-41.
49. Zhang, F., et al., In situ analysis of p16/INK4 promoter hypermethylation in esophageal carcinoma and gastric carcinoma. Chin J Dig Dis, 2004. 5(4): p. 149-55.
50. Abbaszadegan, M.R., et al., Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer, 2005. 36(1): p. 47-54.
51. Hardie, L.J., et al., p16 expression in Barretts esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett, 2005. 217(2): p. 221-30.
52. Schildhaus, H.U., et al., Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 2005. 26(6): p. 1493-500.
53. Schulmann, K., et al., Inactivation of p16, RUNX3, and HPP1 occurs early in Barretts-associated neoplastic progression and predicts progression risk. Oncogene, 2005. 24(25): p. 4138-48.
54. Clement, G., et al., Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barretts oesophagus patients at risk for malignant transformation. J Pathol, 2006. 208(1): p. 100-7.
55. Fukuoka, T., K. Hibi, and A. Nakao, Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma. Anticancer Res, 2006. 26(5A): p. 3333-5.
56. Guo, M., et al., Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res, 2006. 12(15): p. 4515-22.
57. YU, W., et al., [Detection of p16 gene deletion and methylation in esophageal squamous cell carcinoma tissue]. Journal of Zhengzhou University(Medical Sciences), 2006. 141(2): p. 282-284.
58. Guo, X., et al., [Clinical significance of methylation of p16 and FHIT genes in esophageal carcinoma and precancerous diseases]. Tumor, 2006. 26(9): p. 4.
59. Ito, S., et al., Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma. Anticancer Res, 2007. 27(5A): p. 3345-53.
60. Song, C., et al., [Comparative study on p16 gene methylation and expression of esophageal squamous cell carcinoma in high incidence areas]. Chinese Clinical Oncology, 2007. 112(8): p. 570-574.
61. Yang, X., et al., [Analysis on the Methylation of the Promoter of MGMT Gene and p16 Gene in Esophageal Squamous Cell Carcinomma]. Carcinogenesis, Teratogenesis and Mutagenesis, 2008. 20(4): p. 254-257.
62. Miao, L., et al., [Promoter methylation and its significance of hMLH1, E-cadherin and p16INK4a gene in esophageal squamous cell carcinoma]. China Oncology, 2009. 19(5): p. 340-346.
63. Wang, J.S., et al., DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barretts esophagus. Am J Gastroenterol, 2009. 104(9): p. 2153-60.
64. Mohammad Ganji, S., et al., Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients. Dis Esophagus, 2010. 23(7): p. 597-602.
65. Taghavi, N., et al., p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer, 2010. 10: p. 138.
66. Lu, C., et al., Diet folate, DNA methylation and genetic polymorphisms of MTHFR C677T in association with the prognosis of esophageal squamous cell carcinoma. BMC Cancer, 2011. 11: p. 91.
67. Zhao, Y. and Y. Chen, [Study on methylation and expression of p16 in esophageal squamous cell carcinoma in the Hazak and Han nationality]. Journal of XinJiang Medical University, 2011. 34(7): p. 687-690.
68. Yao, Q., et al., [Detection of Promoter Hypermethylation in the Serum of Esophageal Squamous Cell Carcinoma Patient by Nested Methylation-Specific- Polymerase Chain Reaction]. Cancer Research On Prevention and Treatment, 2005. 32(8): p. 3.
69. Ikoma, D., et al., Circulating tumor cells and aberrant methylation as tumor markers in patients with esophageal cancer. Anticancer Res, 2007. 27(1B): p. 535-9.